Top Markets
#1 Threshold Network Threshold Network +65.04%
#2 TENDIES TENDIES +64.30%
#3 Cash Cat Cash Cat +22.24%
#4 OSK OSK +15.86%
#5 Magma Finance Magma Finance +13.64%
#6 Ape and Pepe Ape and Pepe +13.59%
#7 Asteroid Shiba Asteroid Shiba +13.00%
#8 Falcon Finance Falcon Finance +12.81%
#9 Kite Kite +12.56%
#10 龙虾 (Lobster) 龙虾 (Lobster) +11.22%
Coin of the day
Threshold Network Threshold Network
Settings
Language
ENGLISH
Currency
USD
Theme
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Rank in Stocks #17290
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$1.35
Last synced: 2026-09-01
Market Cap
$249.21M
Change (1 day)
1.13%
Change (1 year)
-22.70%
Country
US
Trade Neumora Therapeutics, Inc. Common Stock (NMRA)

Category

Healthcare
P/E ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)
P/E ratio as of 2026 TTM: 0
According to Neumora Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Neumora Therapeutics, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.